Pfizer offloads $3.5 billion stake in Sensodyne-maker Haleon
Reuters
Published Mar 19, 2024 08:24
Updated Mar 19, 2024 14:01
(Reuters) - Haleon (LON:HLN) said on Tuesday top shareholder Pfizer (NYSE:PFE) offloaded a roughly $3.5 billion stake in the consumer healthcare firm, bringing down its holding in the British company to 22.6%.
Pfizer previously held a 32% stake, followed by second-largest shareholder GSK (LON:GSK) which has a 4.2% holding.
WHY IT'S IMPORTANT
This is Pfizer's first stake sale in Haleon since the company was spun off from GSK and listed in 2022 - three years after its formation by combining the pharma giants' consumer healthcare units. Pfizer said last year it planned to cut its ownership in a "slow and methodical" manner within months.
Meanwhile, GSK, which initially held a 12.9% stake, has sold it down over the last year, with the last sale in January.
BY THE NUMBERS
Pfizer sold 594 million shares at a price of 3.08 pounds apiece and about 196.5 million American Depository Shares (ADS), at $7.85 each, which add up to roughly $3.1 billion.
This is higher than the 630 million share sale Haleon had disclosed on Monday. The maker of Sensodyne toothpaste and Advil painkillers said it would also repurchase 315 million pounds ($399.92 million) worth of shares from Pfizer off-market.
WHAT'S NEXT
The stake sale and the buyback is expected to close on March 21 and Pfizer's shares will be subject to a 90-day lock-up period, in connection with the sale.
($1 = 0.7876 pounds)
(This story has been corrected to fix the value of the stake sale to $3.5 bln, from $3.9 bln, in the headline and paragraph 1; also corrects to say stake sale value is $3.1 bln, excluding Haleon's off-market repurchases in paragraph 5; and fixes typo in paragraph 3)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.